|
|
|
17 Nov 2008 |
Life Science Pharmaceuticals Enters Into Agreement with Abbott to Develop Antibody 806
|
|
13 Nov 2008 |
Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months
|
|
13 Nov 2008 |
Antibody Shows Ability to Inhibit Disease in an Established RA Model
|
|
12 Nov 2008 |
Probiogen and Functional Genetics close antibody production agreement
|
|
12 Nov 2008 |
Functional Genetics and ProBioGen close antibody production agreement
|
|
11 Nov 2008 |
Phase 2 Study of IMC-1121B in First-Line Treatment of Advanced Non-Small Cell Lung Cancer Commences Patient Enrollment
|
|
11 Nov 2008 |
Celldex Announces Licensing Agreement for Novel Cancer Antibody Program
|
|
10 Nov 2008 |
Ophthotech Treats First Patient in a Phase I Trial of Monoclonal Antibody, Volociximab, for Age-Related Macular Degeneration
|
|
10 Nov 2008 |
Santaris Pharma Releases Positive Data on LNA-based Survivin Inhibitor
|
|
07 Nov 2008 |
InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
|
|
04 Nov 2008 |
YM Biosciences Reports Data From Exploratory Clinical Trials of Nimotuzumab in Brain Metastases and High-Grade Glioma Presentes at 2008 EORTC-NCI-AACR Annual Meeting
|
|
04 Nov 2008 |
Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
|
|
03 Nov 2008 |
Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
|
|
03 Nov 2008 |
CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
|
|
03 Nov 2008 |
Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer
|
|
01 Nov 2008 |
GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance and Increases RVR Rates in Phase 2 Clinical Trial
|
|
30 Oct 2008 |
New Cimzia(R) study shows rapid reduction of symptoms and progression of rheumatoid arthritis
|
|
30 Oct 2008 |
ERBITUX(R) Supplemental Biologics License Application for First-Line Recurrent or Metastatic Head and Neck Cancer Accepted for Priority Review by U.S. Food and Drug Administration
|
|
30 Oct 2008 |
Biogen Idec Elects to Participate with Genentech in the Development and Commercialization of a Next Generation Anti-CD20 Molecule
|
|
29 Oct 2008 |
Phase 2a Data for MEDI-528 Presented at CHEST 2008
|
|
29 Oct 2008 |
Merck KGaA and Lpath Form Alliance for ASONEP
|
|
28 Oct 2008 |
Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
|
|
28 Oct 2008 |
Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
|
|
28 Oct 2008 |
BioWa Announces License of Biowa's Potelligent(R) Technology to KaloBios Pharmaceuticals
|
|
28 Oct 2008 |
Seattle Genetics Presents on SGN-70 at American College of Rheumatology Meeting
|
|
28 Oct 2008 |
Affitech Acquires Pharmexa's Diabody Technology
|
|
27 Oct 2008 |
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
|
|
27 Oct 2008 |
New data shows ACTEMRA inhibits progression of joint destruction and improves physical function of patients with Rheumatoid Arthritis
|
|
27 Oct 2008 |
Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
|
|
27 Oct 2008 |
Progenics Reports Positive Interim Phase 2 Results for Two Dosage Forms of Novel HIV Therapy PRO 140
|
|
27 Oct 2008 |
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
|
|
27 Oct 2008 |
Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
|
|
27 Oct 2008 |
WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL
|
|
27 Oct 2008 |
New Study Shows ENBREL(R) (etanercept) Is More Effective than a DMARD in the Treatment of Symptoms of Ankylosing Spondylitis Patients
|
|
27 Oct 2008 |
ACZ885 Phase III data show rapid, sustained clinical remission in children and adults suffering from a group of rare, potentially life-threatening autoinflammatory diseases
|
|
27 Oct 2008 |
Data Demonstrate ORENCIA(R) (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Quality in Children With Juvenile Idiopathic Arthritis
|
|
25 Oct 2008 |
New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
|
|
24 Oct 2008 |
Merck KGaA: Erbitux Receives CHMP Positive Opinion for First-Line Use in Head and Neck Cancer
|
|
24 Oct 2008 |
Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs
|
|
23 Oct 2008 |
Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment
|
|
23 Oct 2008 |
XOMA Presents Data On XOMA 052, An Anti-IL-1 Beta Antibody, in Rheumatoid Arthritis and Acute Gout Animal Models
|
|
21 Oct 2008 |
Nerviano Medical Sciences Announces a New Collaboration Agreement With Genentech to Discover Antibody Drug Conjugates
|
|
21 Oct 2008 |
Abbott’s HUMIRA(R) (adalimumab) Data Shows Fistula Healing for Up to Three Years in Patients with Moderate to Severe Crohn’s Disease
|
|
21 Oct 2008 |
CytoDyn Files New IND For Cytolin(R)
|
|
20 Oct 2008 |
Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
|
|
16 Oct 2008 |
Lpath Initiates Dosing in Phase 1 Trial for AMD
|
|
15 Oct 2008 |
Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with Progenics
|
|
10 Oct 2008 |
Biogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid Arthritis
|
|
10 Oct 2008 |
Ablynx Provides an R&D Update Announcing it has Successfully Generated Nanobodies(R) Against GPCRs and Presents New Preclinical Development RANKL Programme
|
|
07 Oct 2008 |
Pivotal Phase III study shows MabThera delays disease progression in patients with relapsed or refractory Chronic Lymphocytic Leukaemia
|
| |
|
Results 1 - 50 of 1155 |
